Therapy Areas
Latest News
Kelun-Biotech publishes phase III data for trastuzumab botidotin in HER2-positive breast cancer
14 September 2026 - Chinese biopharmaceutical company Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) on Monday announced that it has published phase III results for its HER2-targeted antibody–drug conjugate trastuzumab botidotin ...
Armata Pharmaceuticals announces receipt of FDA Breakthrough Therapy Designation for AP-SA02
14 September 2026 - Biotechnology company Armata Pharmaceuticals Inc (NYSE American: ARMP) reported on Monday that it has received U.S. Food and Drug Administration Breakthrough Therapy designation for AP-SA02, its intravenous multi-phage product can...
AstraZeneca's Etcamah misses primary endpoint in Phase III breast cancer trial
14 September 2026 - Biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (NYSE:AZN) disclosed on Monday that its Phase III SERENA-4 trial of Etcamah (camizestrant) in combination with palbociclib did not achieve its primary endpoint of a sta...
GSK reports positive Jideytro data supporting potential first-line lung cancer use
14 September 2026 - Biopharmaceutical company GSK plc (LSE: GSK) (NYSE: GSK) on Monday reported positive registrational Phase I/II ARROS-1 data for Jideytro (zidesamtinib) in previously untreated ROS1-positive non-small cell lung cancer (NSCLC), supp...
Meant Health announces expansion of telehealth access for FDA-approved GLP-1 prescriptions
14 September 2026 - Meant Health, a digital health platform that connects patients with licensed clinicians for evaluation, prescription and ongoing care coaching, announced on Saturday that it is expanding telehealth access to FDA-approved GLP-1 med...
Akeso presents positive results from registrational Phase III study of ivonescimab
14 September 2026 - Chinese biopharmaceutical company Akeso Inc (HK:9926) announced on Sunday the presentation of positive overall survival (OS) results from the randomised, double-blind, multicentre, registrational Phase III HARMONi-2 study (AK112-3...
US FDA grants orphan drug designation for Lundbeck's asedebart
11 September 2026 - Danish biopharmaceutical company H. Lundbeck A/S (CPH: HLUN-B), which focuses on brain health, said on Friday it has received US Food and Drug Administration orphan drug designation for asedebart (Lu AG13909), its investigational ...